M
Martin Mense
Researcher at Cystic Fibrosis Foundation
Publications - 31
Citations - 2110
Martin Mense is an academic researcher from Cystic Fibrosis Foundation. The author has contributed to research in topics: Cystic fibrosis transmembrane conductance regulator & Cystic fibrosis. The author has an hindex of 14, co-authored 20 publications receiving 1463 citations. Previous affiliations of Martin Mense include Rockefeller University.
Papers
More filters
Journal ArticleDOI
A revised airway epithelial hierarchy includes CFTR-expressing ionocytes
Daniel T. Montoro,Adam L. Haber,Moshe Biton,Moshe Biton,Vladimir Vinarsky,Brian M. Lin,Susan E. Birket,Feng Yuan,Sijia Chen,Hui Min Leung,Jorge Villoria,Noga Rogel,Grace Burgin,Alexander M. Tsankov,Avinash Waghray,Michal Slyper,Julia Waldman,Lan Nguyen,Danielle Dionne,Orit Rozenblatt-Rosen,Purushothama Rao Tata,Hongmei Mou,Manjunatha Shivaraju,Hermann Bihler,Martin Mense,Guillermo J. Tearney,Steven M. Rowe,John F. Engelhardt,Aviv Regev,Aviv Regev,Jayaraj Rajagopal +30 more
TL;DR: ‘pulse-seq’ is developed, combining scRNA-seq and lineage tracing, to show that tuft, neuroendocrine and ionocyte cells are continually and directly replenished by basal progenitor cells, establishing a new cellular narrative for airways disease.
Journal ArticleDOI
Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.
Hongmei Mou,Vladimir Vinarsky,Purushothama Rao Tata,Karissa Brazauskas,Soon H. Choi,Adrianne K. Crooke,Bing Zhang,George M. Solomon,Brett Turner,Hermann Bihler,Jan Harrington,Allen Lapey,Colleen L. Channick,Colleen Keyes,Adam Freund,Steven E. Artandi,Martin Mense,Steven M. Rowe,John F. Engelhardt,Ya-Chieh Hsu,Jayaraj Rajagopal +20 more
TL;DR: This work shows that dual inhibition of SMAD signaling pathways enables robust expansion of primary epithelial basal cell populations in airway epithelia, and finds that TGFβ/BMP/SMAD pathway signaling is strongly activated in luminal and suprabasal cells of several epithelium, but suppressed in p63+ basal cells.
Journal ArticleDOI
In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer
TL;DR: The observed crosslinks demonstrate that NBD1 and NBD2 interact in a head‐to‐tail configuration analogous to that in homodimeric crystal structures of nucleotide‐bound prokaryotic NBDs.
Journal ArticleDOI
“CFTR Modulator Theratyping: Current Status, Gaps and Future Directions”
John P. Clancy,Calvin U. Cotton,Scott H. Donaldson,George M. Solomon,Donald R. VanDevanter,Michael P. Boyle,Martina Gentzsch,Jerry A. Nick,Beate Illek,John C. Wallenburg,Eric J. Sorscher,Margarida D. Amaral,Jeffrey M. Beekman,Anjaparavanda P. Naren,Robert J. Bridges,Philip Thomas,Garry R. Cutting,Steven M. Rowe,Anthony G. Durmowicz,Martin Mense,Kris De Boeck,William R. Skach,Christopher M. Penland,Elizabeth Joseloff,Hermann Bihler,John Mahoney,Drucy Borowitz,Katherine L. Tuggle +27 more
TL;DR: CFTR modulator theratyping is a novel and rapidly evolving field that has the potential to identify rare CFTR variants that are responsive to approved drugs or drugs in development.
Journal ArticleDOI
Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening
Ori Kalid,Martin Mense,Sharon Fischman,Alina Shitrit,Hermann Bihler,Efrat Ben-Zeev,Nili Schutz,Nicoletta Pedemonte,Philip Thomas,Robert J. Bridges,Diana R. Wetmore,Diana R. Wetmore,Yael Marantz,Hanoch Senderowitz +13 more
TL;DR: It is hypothesized that compounds binding at inter-domain interfaces may improve the stability of the protein, potentially affecting the folding yield or surface stability, and may prove to be better leads for the development of CF therapeutics than either pure correctors or pure potentiators.